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Abstract 
 
Infections caused by methicillin-resistant Staphylococcus aureus (MRSA) 
are increasingly considered as a main health concern worldwide for 
hospitalized patients. The prevalence of community-acquired infections has 
risen continuously during the last few years. Therefore, the control of MRSA 
spread is now more important than ever. 
This study was performed to investigate the prevalence of S. aureus nasal 
carriage among 843 patients admitted to Ramallah hospital and 72 health 
care workers (HCW) between October 2003 and October 2004, and to 
determine phenotypic (antibiogram) and genotypic (Multilocus Restriction 
Fragment Typing) characteristics of MRSA isolates. 
The prevalence of S. aureus nasal carriage among patients and HCW was 
25.8 and 20.8 % respectively. The prevalence of MRSA isolates among 
S. aureus from patients and HCW was 6.8 and 66.6 % respectively. Eleven 
antibiogram types were characterized for the 28 MRSA isolates by using 10 
different antibiotics. The most predominant antibiogram was antibiogram I 
and was observed among 46.4 of all MRSA isolates. All isolates were 
completely resistant to penicillin and ampicillin, while all isolates were 100  
 
XI 
% susceptible to teicoplanin and vancomycin. However, the susceptibility to 
ciprofloxacin, Erythromycin, gentamycin, and clindamycin was 71.5 %,   
82.2 %, 85.8 % and 89.3 % respectively. By using MLRFT method, the 28 
MRSA isolates were differentiated into eight restriction fragment types 
(RFTs). Twenty-two (78.5 %) of the 28 isolates were grouped into four 
RFTs. The remaining six MRSA isolates were assigned to four additional 
RFTs. 
Four of the common MRSA RFTs observed in this study could be 
provisionally identified as belonging to sequence types of known clonal 
lineages. Where the RFTs genotypes – CAAACAC, AAACCAA , 
BBBBBAB and BAAACAC correspond to the archaic/Iberian/clone V 
group, the NewYork/Pediatric/Japan group, the epidemic MRSA type 16 
(EMRSA – 16) group, and the Brazilian clone respectively. The other RFTs 
retrieved in this study did not correspond to any of the major lineages that 
spread internationally. 
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زات العٌقْدٗة الوقاّهة للوضاد الحْٕ٘ ه٘ث٘س٘ل٘ي اُحواها خاصا لواا جساههَ هاي هلاا   جسححْذ الوكْ
اذ اى ّجْدُا لن ٗقحصس علٔ الوسضٔ فٖ الوسحلف٘ات ّاًواا اصاهحث جعاص  , صح٘ة فٖ العالن اجوع
 .اٙى هي الٌاض فٖ الوجحوع
 843وضااد  للو٘ث٘سا٘ل٘ي فاٖ جوث ُرٍ الدزاسة للححقق هي ًسهة ّجاْد العٌقْدااات الرُه٘اة اواا فِ٘اا ال 
ّ ارل  جحدٗاد  4003ّجلاسٗي  8003هسٗض دخ  هسحلفٔ زام الله فٖ الفحس  الْاقعة ها اا٘ي جلاسٗي 
 sucolitlumًسااهة هقاّهااة ُاارٍ العااصمت لعااد  هضااادات  ْ٘ٗااة ّهااي  اان جحل٘لِااا جٌ٘٘ااا ااسااحعوا  
 .gnipyt tnemgarf noitcirtser
 3.03ّ 3..3فٖ اًف الوسضٔ ّالووسض٘ي الارٗي جان دزاساحِن العٌقْدٗات الرُه٘ة   اًث ًسهة ّجْد
فااٖ الوسضاأ فااٖ  اا٘ي اى ًسااهة العٌقْدٗااات الرُه٘ااة الوقاّهااة للوضاااد الح٘اإْ ه٘ث٘ساا٘ل٘ي . جحااع٘ااا
 .جحااع٘ا اٗضا  8.88ّ  3.8ّالووسض٘ي ُٖ 
امخسٓ  واا ّقد  اًث ًسهة  ساس٘ة العصمت الوقاّهة للوضاد الحْٕ٘ ه٘ث٘س٘ل٘ي للوضادات الحْ٘ٗة 
لك  هاي س٘هسّفلْ ساسا٘ي، اٗسّ سّهاٗسا٘ي، جٌحاهاٗسا٘ي  8..3، 3..3، % 3.33،%  ...5: : ٗلٖ
جو٘ع العٌ٘ات  اًث غ٘س هقاّهاة للفاًكْهاٗسا٘ي، غ٘اس اى جو٘عِاا  اًاث هقاّهاة . ّ لٌداهاٗس٘ي جحااع٘ا
 . للهٌسل٘ي
عٌ٘اااااااااة الحاااااااااٖ جاااااااان جحل٘لِاااااااااا الااااااااأ  33فقاااااااااد جْشعااااااااث ا  TFRLM ااسااااااااح دام ا  
ا ٌاا ّعلاسّّى عصلاة هاي الثوااًٖ ّالعلاسّى جٌحواٖ الأ  sepyt tnemgarf.noitcirtseR.  وااًٖ 
، اهاااا العاااصمت الساااث الهاق٘اااة فححاااْش  علااأ ازااااع  sepyt tnemgarf noitcirtseRازااااع 
 . اضاف٘ة sepyt tnemgarf noitcirtseR
الهٌ٘اة . ة الٔ سلالة هعٌ٘ةالسااقة اى جٌحوٖ ّاصفة هؤقح sTFR ASRMهي الووكي اى ازاعة هي ا  
 CACAAAB dna BABBBBB ,AACCAAA ,DACAAAC-  ُٖ  sTFRالْزا ٘ة   
 /cirtaidep/kroy weN، هجوْعااة Venolc/nairebI/caihcrAّالحااٖ جحْافااق هااع هجوْعااة 
، ّالوجوْعاة الهساشٗل٘اة 61-ASRME(( 8.ًاْ   ASRM، هجوْعاة ّااا   puorg esenapaJ
الوكحلافة فاٖ ُارٍ الدزاساة لان جحماااق هاع لٕ هاي السالامت الوٌحلاس   sTFR اهاا اق٘اة ا . االحسج٘ا 
 .عالو٘ا
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1 
 
1. Introduction 
The genus Staphylococcus is a member of the family Micrococcacea. It is 
composed of 33 species, 17 of which may be encountered in human clinical 
specimens. Staphylococcus aureus subsp. aureus is by far the most 
important human pathogen among the staphylococci (13). S. aureus is 
regarded as one of the most significant pathogens, causing both nosocomial 
and community-acquired infections (28). 
The incidence of community-acquired and hospital acquired S. aureus 
infections has been rising with increasing emergence of drug-resistant strains 
referred to as methicillin-resistant S. aureus (MRSA). MRSA is an 
established pathogen in most health care facilities. Previously limited to 
hospitals, MRSA infections have been increasingly reported in the 
community (31).   
 
 
 
 
 
 
1.1 Staphylococcus aureus  
 1.1.1 Laboratory diagnosis 
Staphylococcus aureus grows as gram positive cocci in clusters; it is catalase 
and coagulase positive facultative anaerobe that shows beta hemolysis on 
sheep blood agar (13). 
Laboratory diagnosis of S. aureus is based on phenotypic characteristics and 
biochemical tests: typical colonial morphology appears as large yellow or 
grey colonies, coagulase positive, fermentation of mannitol and the 
production of heat stable nucleases. Coagulase production is considered the 
most reliable characteristic for identifying S. aureus. A four-hour tube 
coagulase test is a definitive test. A slide test is used as a screening method 
for the detection of the clumping factor. Latex agglutination tests are also 
used as rapid identification tests (13).  
1.1.2 Diseases 
Staphylococus aureus is a major pathogen, responsible for a wide spectrum 
of diseases (28), ranging from relatively benign infections to life threatening 
systemic illnesses. S. aureus is a common cause of skin infections such as 
folliculitis, impetigo, furuncles and carbuncles. It is also commonly 
associated with wound infections, Toxic Shock Syndrome (TSS) and food 
poisoning. More serious infections may be also caused by S. aureus such as 
pneumonia, mastitis, meningitis, endocarditis, osteomylitis and bacteremia 
(13, 53). 
1.1.3 Colonization 
S. aureus presents as normal flora of different body sites (13). Colonization 
may be transient or persistent at a single site or multiple body sites (53). The 
anterior nares are the most common site of colonization; other sites include 
intertriginous skin folds, perineum, axillae and the vagina (13, 53). Some 
patients are more often colonized than others by S. aureus such as newborns, 
intravenous drug users, diabetics, patients with skin diseases and 
hemodialysis patients.  
As with methicillin susceptible S. aureus, most persons who are colonized 
with MRSA are not infected (53). However, significant proportions – at least 
30 % - of hospitalized patients who become colonized with MRSA 
eventually have an MRSA infection such as pneumonia, bacterimia, or 
wound infection (46, 53). 
Common risk factors for the acquisition of MRSA include increasing age, 
admission to intensive care units, previous hospitalization, invasive 
procedures and over use of antibiotics (53).  
 
 
1.1.3.1 Nasal carriage of S. aureus 
Although S. aureus can be cultured from multiple sites of the skin and 
mucosal surfaces of carriers, the primary reservoir of staphylococci is 
thought to be the anterior nares (26). Nasal carriage rates of 25 % - 40 % 
have been reported, and are known to be influenced by ethnicity, age, 
exposure to antibiotics and the hospital environment (34). 
Carriage of S. aureus in the nose appears to play a key role in the 
epidemiology and pathogenesis of infection (16, 26). Additionally, nasal 
carriage of S. aureus has been identified as a risk factor for the development 
of infections in various settings (26). 
Several studies suggested that MRSA carriage constitutes a greater risk for 
the development of S. aureus infection than does MSSA carriage. This could 
be a result of the resistance itself of an increased intrinsic virulence of 
MRSA compared with MSSA or of a more vulnerable category of patients 
being colonized by MRSA (26, 29, 35). Elimination of nasal carriage would 
theoretically reduce the infection rates in populations in which it has been 
identified as a risk factor (26). 
 
 
 
1.1.4 Mode of transmission 
S. aureus including MRSA strains are primarily spread from patient to 
patient via the transiently colonized hands of health-care workers during 
patient contact or handling of contaminated materials (46, 53). 
Environmental surfaces are not thought to play a major role in transmission 
except in special populations such as patients in burn units or intensive care 
units. Airborne transmission of S. aureus has been reported but does not 
appear to be an important mode of spread, except possibly in burn units (53). 
The cohort of colonized or infected MRSA patients usually constitutes the 
most significant in-hospital reservoir from which MRSA is transmitted to 
other individuals (46). Because spread of MRSA in health care settings is 
often clonal, hand hygiene and barrier precautions are often effective in 
interrupting its spread. Targeted surveillance for MRSA is also a useful aid 
for infection control (61). 
1.1.5 Treatment 
Most strains of S. aureus are treated with penicillin –type antibiotics, such as 
flucloxacillin, cloxacillin, dicloxacillin and methicillin. Alternative 
antibiotics, such as erythromycin, may be used in persons who are allergic to 
penicillin. Treatment of MRSA infections remains difficult due to the 
multiple resistant of these strains. Vancomycin is the drug of choice. 
Teicoplanin and daptomycin are two investigational antibiotics related to 
vancomycin in structure and in spectrum of activity (10). Mild to moderately 
severe MRSA infections may be treated with trimethoprim-
sulfamethoxazole or minocycline if the organism is susceptible to these 
agents. Although most strains are currently susceptible to rifampin and 
fusidic acid, these agents should not be used alone because of the risk for 
selecting resistant mutants during treatment (53).   
1.2 Methicillin Resistant S. aureus 
1.2.1 The evolutionary origin of MRSA: 
After methicillin was introduced into clinical practice in 1959, resistant 
strains of Staphylococcus aureus (MRSA) appeared, bearing a newly 
acquired resistant gene, mecA that encodes an altered penicillin binding 
protein. The origin of the mec element is still unclear (8). A mecA like gene 
with more than 80 % sequence homology to the MRSA mecA is found in all 
strains of the animal species Staphylococcus scuiri. Therefore, leading to the 
hypothesis that S. scuiri mecA gene may be an evolutionary relative of the 
PBP- encoding S. aureus mecA, although the native S. scuiri mecA gene 
does not confer methicillin resistance (8, 11). 
The mode of transfer of the mec gene from an unknown donor to S. aureus 
is poorly understood (17). However, two hypotheses have been raised to 
explain this issue (21): The single clone hypothesis which suggests that 
mecA entered the S. aureus population on one occasion and resulted in the 
formation of a single MRSA clone that has since spread around the world 
(27). While the second hypothesis proposes that MRSA have emerged on 
various occasions giving different clonal lineages (18).  
 1.2.2 Methicillin Resistance in Staphylococcus aureus 
 Methicillin was synthesized to treat infections caused by penicillin-resistant 
staphylococcus aureus. Unfortunately, as soon as it was used clinically, 
methicillin- resistant S. aureus strains were isolated (11, 56, 18). Resistance 
was termed intrinsic because it was not due to the production of beta-
lactamase (11, 56). 
The main mechanism of methicillin resistant in S. aureus is through the 
expression of a foreign PBP, PBP2a that is encoded by mecA gene (56, 62). 
Normally, staphylococcus aureus strains produce four major penicillin  
binding proteins (PBPs), PBP1, 2, 3 and 4 with approximate molecular 
masses of 85, 81, 75, 45 KDa, respectively (11). These proteins are the 
enzymes that catalyze the transpeptidation reaction that cross-links the 
peptidoglycan of the bacterial cell wall (11, 56). PBPs are also the first 
targets of beta-lactams (8). PBPs 1, 2 and 3 that have high affinity for most 
beta-lactam antibiotics are essential for cell growth and for the survival of 
susceptible strains, and binding of beta-lactams to these PBPs is lethal (11).  
In methicillin resistant cells PBP2a is expressed in addition to the usual 
PBPs (11, 56, 24). PBP2a has low affinity for beta-lactam antibiotics, so that 
it can substitute for the essential functions of high affinity PBPs at 
concentrations of antibiotic that are otherwise lethal (11, 56, 7). 
PBP2a is encoded by mecA gene, which is located on a mobile genetic 
element, Staphylococcal chromosomal cassette mec (SCCmec). The 
SCCmec is horizontally transferable among staphylococcal species and has 
no allelic equivalent in susceptible strains (8, 25). The mec element is 
always found near the pur-nov-his gene cluster on the S. aureus 
chromosome (11). In addition to the structural gene mecA, the mec element 
contains mecI and mecR1 which are regulatory elements controlling mecA 
transcription and the additional mec associated DNA (11, 8). The mec 
element also carries attachment sites for transposons and at least one IS 
257(IS431mec). The later sequence acts as a trap for the capture of further 
IS257- linked resistant determinants and resistance plasmids. This leads to 
clustering of multiple resistant in that part of the DNA (62). 
Several genes have been implicated in regulating mecA gene transcription. 
These include the beta-lactams regulatory sequences, blaR1-blaI, and the 
analogous and partially homologous chromosomal sequences; mecR1-mecI 
(40, 11, 56, 8). mecA gene expression varies among strains (11) and the 
strain’s genetic background profoundly influences the methicillin resistance 
phenotype (67). Chromosomal genes independent of SCCmec, for example, 
determine whether a strain is homogeneous or heterogeneous in its pattern of 
resistance (25). Moreover, environmental conditions such as pH, 
temperature and salt concentration can influence the expression of the mecA 
gene (methicillin resistance). 
Other mechanisms with low-level of methicillin resistance have been 
described. These mechanisms are distinct from true methicillin resistance, 
and can result from the production of large amounts of beta-lactamase, or 
increased production and /or modified penicillin binding capacity of normal 
PBPs (11). 
1.2.3 Types of resistance 
Homogeneous resistance: it refers to a cell population where all the cells are 
resistant to high concentrations of methicillin (56, 40). The nature of the 
chromosomal mutations that give rise to homogeneous resistance are not 
known but mutations in the newly described hmr loci may be involved in 
some cases (56).  
Heterogeneous resistance: The majority of cells in heterogeneous strains 
(typically 99.9 or more) are susceptible to low concentrations of beta-lactam 
antibiotics, with only a small proportion of cells growing at high methicillin 
concentrations (11, 40 , 8, 56). The small minority of cells that exhibit high 
level resistance in the heterogeneous population are due to an additional 
chromosomal mutation that occurs outside the mec element (56).   
 1.2.4 Community acquired MRSA:  
A significant increase in the occurance of infections caused by community – 
acquired MRSA (CA-MRSA) has been reported in different areas of the 
world during the past ten years (14). CA-MRSA has been shown to cause 
infections in children and young adults who did not present with classical 
risk factors for nosocomial infections (50, 61, 12). Frequently, these isolates 
were associated with skin and soft tissue diseases. However, more severe 
infections such as highly lethal necrotizing pneumonia have been reported 
(50, 14). 
CA-MRSA isolates are not clonally related to hospital acquired MRSA (HA-
MRSA) international clones (50). A novel genetic mobile element 
designated SCCmec type IV has been identified in these isolates (14, 42, 
12). In contrast to HA-MRSA, CA-MRSA tends to be susceptible to most 
non beta- lactam antibiotics (14, 12, 50). 
The origins of these community-acquired strains of MRSA are subject to 
debate. One possibility is that MRSA strains of nosocomial origin may be 
transmitted in the community through discharged hospital patients or health 
care workers. Another possibility could be of horizontal transfer of the 
methicillin resistance determinant into a formerly susceptible background 
(12). 
1.2.5 Prevalence of MRSA: 
The prevalence of MRSA among the S. aureus isolates differs widely among 
different countries as well as from one hospital to another in the same 
country (55). Its prevalence is consistently higher in the United States, Japan 
and Southern Europe than in other countries. More than 30 % of individuals 
in these countries are infected, compared with less than 2 % in Scandinavia, 
the Netherlands and Switzerland (22). 
The actual prevalence of community acquired MRSA cannot be accurately 
determined but it is estimated that 40 % of adult cases may be acquired 
outside the hospital (12, 70). 
 1.3 MRSA Typing: 
Nosocomial infections caused by methicillin resistant strains of S. aureus 
(MRSA) belong to the most important multiresistant pathogens world-wide 
(57). The increase of the frequency of MRSA and the possibility of 
emergence of resistance to vancomycin demands a quick characterization of 
isolates and identification of clonal spread within hospitals (63). 
Bacterial strain typing distinguishes related or clonal isolates from unrelated 
isolates (52). It has become an important clinical tool to investigate 
suspected outbreaks and to evaluate nosocomial transmission (52). It is also 
needed for providing information on changes in the MRSA population 
during long-term surveillance and to deduce the evolution and global spread 
of these strains. 
Numerous typing methods focus on discriminating MRSA isolates. These 
methods can be characterized in terms of typeability, reproducibility, 
discriminatory power and ease of interpretation (60, 32). The choice of the 
typing method varies depending on the application (44).  
Typing methods fall into two broad categories: phenotypic methods and 
genotypic methods (as shown in the next sections).  
1.3.1 Phenotypic methods: 
 Before the era of molecular typing, phenotypic techniques such as 
biotyping, serotyping, antimicrobial susceptibility and phage typing have 
been used (63). These methods characterize the products of a certain gene in 
order to differentiate strains (60). Such systems are inherently limited by the 
capacity of bacteria to alter the expression of the characteristic being 
assessed. Thus, independent isolates of the same strain can vary 
phenotypically. In addition, some of these approaches such as phage typing 
technique are limited by the relatively large fraction of strains that appear 
phenotypically null and consequently are non-typeable (32).       
Although, the application of the phenotypic techniques has been decreased, 
they may be still useful for discrimination of clinical isolates (57). 
 1.3.2 Genotypic methods: 
 Genotyping methods are those based on the analysis of the genetic structure 
of an organism (60, 52). These methods are less subject to natural variation 
than phenotypic methods, although they can be affected by insertions or 
deletions of DNA into the chromosome, the gain or loss of 
extrachromosomal DNA or random mutations that may create or eliminate 
restriction endonuclease sites (60). 
With the advent of molecular biology, several genotypic techniques have 
been developed. Initial techniques compared restriction endonucleases 
patterns of chromosomal or plasmid DNA. The second generation of 
genotyping methods included southern blot hybridization using gene-
specific probes, ribotyping, polymerase chain reaction (PCR) based 
approaches and pulsed field gel electrophoresis (52, 59, 32). Recently PCR 
and DNA sequencing methods such as multilocus sequence typing and 
single locus sequence typing have been advanced (17, 52). 
1.3.2.1 Multilocus Restriction Fragment Typing (MLRFT): 
Molecular typing of S. aureus has been used to examine both long-term or 
global epidemiology and short-term or local epidemiology (44). Pulsed field 
gel electrophoresis (PFGE) is generally regarded as the most discriminatory 
technique for strain identification, particularly in the context of identifying 
strains involved in local outbreaks (5, 17, 36, 44).  A major disadvantage of 
PFGE and all methods that depend on comparison of DNA fragment patterns 
on gels is the difficulty of comparing the results from different laboratories 
(17, 5, 30). Moreover, there is no convenient metric scale that reliably 
measures genetic relationships among strains with substantially different 
PFGE patterns (5). These features limit the value of PFGE as a tool for 
investigating the population genetics and global epidemiology of S. aureus 
(5, 17). These problems are overcome through the use of multilocus 
sequence typing (MLST) and Spa typing (5, 18, 30). 
Multilocus sequence typing (MLST) is a highly discriminatory method of 
characterizing bacterial isolates on the basis of the sequences of 450 bp 
internal fragments of seven house-keeping genes (30). Sequence data are 
portable and are easily analyzed to provide measures of genetic relationships 
and population structures (5) 
Unfortunately, neither PFGE nor the sequence-based approaches are 
conveniently applied in a clinical setting. Both require specialized 
equipment and are relatively costly and time consuming (5).  
MLRFT is a rapid, low cost strain typing technique based on restriction 
fragment (RF) pattern analysis of the seven loci used in MLST. It captures 
about 95 % of the between-strain genetic variability detected by MLST. 
Moreover, by basing MLRFT on the same seven loci used in MLST, it is 
possible to systematically link MLRFT results to the MLST sequence 
database. MLRFT thus has value both as a convenient stand-alone technique 
for strain typing and as a rapid screening technique to categorize strains for 
targeted PFGE and/or MLST analysis (5). 
 
  
 
 
 
 
 
1.4 Aims of the study 
Nosocomial infections due to MRSA are continuing to be a major health 
concern world-wide. Furthermore, reports of infections caused by S. aureus 
with reduced susceptibility to vancomycin (the drug of choice for MRSA 
infections) have increased these concerns (54). 
In these terms, monitoring and limiting the spread of MRSA strains remains 
a primary focus of most hospital infection control programs. Increased 
surveillance, including the screening of high risk patients has been 
recognized as an important component of effective hospital infection control 
programs (34). 
In Palestine, clinical isolates of Staphylococcus aureus resistant to 
methicillin and other antibiotics are present; however, data describing their 
prevalence, patterns of resistance, genetic and epidemiological relatedness 
have not been investigated. Therefore, the aims of this study are to: 
1. Investigate the prevalence of MRSA among isolates collected from the 
anterior nares of 843 patients admitted to Ramallah hospital and 72 HCW 
between October 2003 and October 2004. 
2. Characterize methicillin-resistant S. aureus isolates by using phenotypic 
(antibiogram) and genotypic (MLRFT) methods. 
3. Determine the resistance profiles of MRSA strains against several 
antibiotics. 
4. Compare the common MRSA strains in Palestine with the internationally 
recognized strains.  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
                                                  
Chapter 2 
2. Materials and methods 
 2.1 Collection of S. aureus isolates 
Ramallah hospital is the main general hospital in Ramallah. It has 136 beds 
distributed in six wards: medical, surgical, obstetrics, pediatrics including 
the neonatal unit, intensive care unit and the cardiac surgery intensive care 
unit. 
Study design and data collection: 
A total of 843 patients admitted to Ramallah hospital were screened for 
nasal carriage of S. aureus at their admission between October 2003 and 
October 2004. A second nasal swab has been taken from patients who stayed 
more than 5 days in the hospital. Isolates of S. aureus recovered from 
patients who had enrolled in the study and developed an infection later were 
also collected. Moreover, a group of 72 health care workers from Ramallah 
hospital were screened for nasal carriage of S. aureus. 
 2.2 Identification of S .aureus  
 Carriage of S. aureus was determined by obtaining nasal swab specimens 
from both anterior nares of patients. The swabs were streaked on mannitol 
salt agar, and the plates were incubated at 35°C and examined after 24 hours 
and 48 hours of incubation. Colonies that have been suspected to be S. 
aureus were cultured on blood agar and tested for production of catalase, 
coagulase and DNAse. Isolates that have been confirmed to be S. aureus 
were stored at –70°C in tryptic soy broth containing 15 % glycerol for 
further investigation (44). 
2.3 MRSA Determination 
2.3.1 Oxacillin susceptibility 
Screening for methicillin resistant S. aureus isolates were detected by using 
the disk diffusion method outlined by the National Committee for Clinical 
Laboratory Standards (NCCLS) (38). By using this method 1μg oxacillin 
disks were placed on Muller-Hinton agar (oxoid, United Kingdom) 
supplemented with 4 % NaCl. The inoculum size was adjusted to a final 
concentration of 10
5
 CFU/ml. Zones of inhibition were measured following 
incubation at 35°C for 24 hours. A zone diameter of < 10 mm was 
considered as indicative of resistance. 
2.3.2 Detection of mecA gene 
Resistance to methicillin was confirmed by PCR-based detection of the 
mecA gene as descried previously (37). PCRs were carried out in 25 µl 
reaction volumes. Each reaction contained 2.5 µl of 10X Taq buffer, 0.2 mM 
of each dNTP (Invitrogen; UK), 0.5 µM of each sense and anti sense  
primer, 1.25 U of Taq DNA polymerase (Invitrogen; UK) and 2.5 µl of 
chromosomal DNA. Thermal cycling was performed in PTC-150 DNA 
engine, with an initial 5 min denaturation at 95ºC, followed by 35 cycles of 
denaturation at 95°C for 30 seconds, annealing at 55ºC for 1 min and 
extension at 72ºC for 1 min, followed by a final extension step at 72ºC for 5 
min. The primers that have been used are listed in Table 1. 
 2.4 Antimicrobial Susceptibility Testing 
The susceptilities of all S. aureus isolates to different antibiotics were tested 
by the agar disk diffusion method on Muller- Hinton agar (oxoid, Uk) as 
standardized by the National Committee for Clinical Laboratory Standards 
(NCCLS) (38). Tested antibiotics included: ciprofloxacin 5 μg, penicillin 10 
μg, gentamycin 10 μg, tetracycline 30 μg, clindamycin 2 μg, ampicillin 10 
μg, teicoplanin 30 μg, erythromycin 15 μg, vancomycin 30 μg, oxacillin 1 
μg and cephalothin 30 μg. The inoculum size was adjusted to a final 
concentration of 10
5
 CFU/ml and zones of inhibition were measured after 24 
hours of incubation at 35°C. 
 
 
 
 
 
2.5 Multilocus Restriction Fragment typing (MLRFT) 
2.5.1 DNA Extraction 
DNA extraction was carried out by using the rapid lysis method (65): 
Bacteria were harvested from blood agar plates (one loopful, by using a 1µl 
loop). Cells were resuspended in 50 µl of lysostaphin (100 µg/ml in water; 
Sigma chemical Co., USA). Cell suspensions were incubated at 37ºC. After 
10 min, 50 µl of proteinase K solution (100 µg/ml, Sigma, USA) and 150 µl 
buffer (0.1 M Tris, PH 7.5) were added. Cell suspensions were incubated for 
an additional 10 min at 37°C and then placed in a boiling water bath for 5 
minutes. The mixture was centrifuged at 2000 rpm for 1 minute and the 
supernatant containing the chromosomal DNA was used for PCR.  
2.5.2 PCR  
PCRs were carried out with 50 µl reaction volumes. Each reaction contained 
5 µl of 10X Taq buffer, 0.2 mM of each dNTP (Invitrogen; United 
Kingdom), 1 µM of each sense and antisense primer, 1.25 U of Taq DNA 
polymerase (Invitrogen; United Kingdom) and 5 µl of chromosomal DNA. 
Thermal cycling was performed in PTC-150 DNA engine, with an initial 5 
min denaturation at 95ºC, followed by 30 cycles of denaturation at 95°C for 
30 seconds, annealing at 55ºC for 1 min and extension at 72ºC for 1 min, 
followed by a final extension step at 72ºC for 5 min.  
2.5.2 Multilocus Restriction Fragment Typing (MLRFT) 
Amplicons were directly subjected to digestion with restriction 
endonucleases by adding 10 µl of DNA amplicon to 20 µl of a reaction 
mixture containing 3 µl of 10x appropriate digestion buffers and 5 U of 
restriction enzyme. The restriction reaction was incubated at the optimal 
temperature for each respective restriction enzyme, as recommended by the 
manufacturer, for 2-4 hours. Complete digestion was achieved without prior 
purification of the PCR amplicon. The restriction enzyme or combination of 
restriction enzymes used for each locus are listed in table (2). CfoI and DdeI 
were purchased from Roche, Switzerland, while all other restriction enzymes 
were purchased from Fermentas, Lithuania. 
RFs were separated by electrophoresis on 4.0 % agarose gel (Sigma, USA), 
and were sized against a 50-bp DNA ladder (Roche, Switzerland). The gels 
were visualized under UV illumination. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Sequences of PCR primers  
 
         Target gene                     Primer name                       Sequence (5’-3’) 
 
Carbamate Kinase (arcC) 
 
arcC-Up 
arcC-Dn 
 
TTGATTCACCAGCGCGTATTGTC 
AGGTATCTGCTTCAATCAGCG  
 
 
Shikimate dehydrogenase 
(aroE) 
 
aroE-Up 
aroE-Dn 
 
ATCGGAAATCCTATTTCACATTC 
GGTGTTGTATTAATAACGATATC 
 
 
Glycerol Kinase (glpF) 
         
     glpF-Up 
glpF-Dn 
 
CTAGGAACTGCAATCTTAATCC 
TGGTAAAATCGCATGTCCAATTC 
 
 
Guanylate Kinase (gmk) 
 
gmk-Up 
gmk-Dn 
 
ATCGTTTTATCGGGACCATC 
TCATTAACTACAACGTAATCGTA 
 
 
Phosphate 
acetyltransferase (pta) 
 
pta-Up 
pta-Dn 
 
GTTAAAATCGTATTACCTGAAGG 
GACCCTTTTGTTGAAAAGCTTAA 
 
 
Triosephosphate 
isomerase (tpi) 
 
tpi-Up 
tpi-Dn 
 
TCGTTCATTCTGAACGTCGTGAA 
TTTGCACCTTCTAACAATTGTAC 
 
 
Acetyl coenzyme A 
acetyltransferase (yqiL) 
 
YqiL-Up 
YqiL-Dn 
 
CAGCATACAGGACACCTATTGGC 
CGTTGAGGAATCGATACTGGAAC 
 
mecA gene 
 
     MecA-Up 
     MecA-Dn 
 
AAAATCGATGGTAAAGGTTGGC 
AGTTCTGCAGTACCGGATTTGC 
 
 
 
 
 Table 2. Restriction endonucleases used in MLRFT 
 
 
Locus Size of 
product (pb) 
No. of MLST   
alleles/locus 
Restriction 
enzyme(s) 
No. of MLRFT  
Alleles/locus 
arcC 570 37 HinfI 3 
aroE 536 66 AluI & CfoI 5 
glpF 543 44 Tsp5091 9 
gmk 488 35 CfoI 5 
pta 575 44 RsaI 7 
tpi 475 58  BbuI & MboI 4 
yqiL 598 52  VspI & DdeI 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 
 
3. Results 
 
Bacteriological screening:  
A total of 843 patients admitted to Ramallah hospital were enrolled in the 
study. Nasal swabs were obtained from patients and screened for the 
presence of S. aureus. The presence of S. aureus in nasal swab samples was 
confirmed by recovery of the S. aureus from mannitol salt agar and a 
positive test for catalase, coaglase and DNase. From the 843 patient samples, 
218 isolates of S. aureus were isolated. Nasal carriage percentage of S. 
aureus differs among wards with a range of 17.4 % to 31.1 %. The medical 
ward showed the highest rate of 31.1 % while the surgical ward showed the 
lowest rate of 17.4% as shown in Table 3. 
From the 218 isolates of S. aureus, a total of 15 specimens were found to be 
positive for MRSA in all wards of the hospital. The prevalence of MRSA 
isolated from the different wards ranged from 0 % to 33.3 %. The medical 
ward showed the highest rate of 33.3 % while no MRSA was isolated from 
OBS as shown in Table 3. 
As shown in Table 4, a total of 72 health care workers (HCW) were screened 
for S. aureus carriage. S. aureus was isolated from 15 HCWs giving a 
prevalence of 20.8 %. Among the 15 HCW positive for S. aureus, 10 isolates 
were found to be positive for MRSA giving a percentage of 66.6 %.  
Eight patients enrolled in this study have developed S. aureus infection after 
the first sample. Two of these patients were carriers for the organism, 
whereas the others were not. One of these eight clinical isolates was 
methicillin resistant S. aureus (Data not shown). 
Another swab has been taken for 65 patients after one week of their 
admission to the hospital. Forty three of these patients were not S. aureus 
carriers at the time of admission. After one week four patients have a 
positive result, in which one of them was MRSA. The other 22 patients were 
carriers at their admission to the hospital and after one week, 13 of them 
have negative results mostly because of antibiotic treatment, while the other 
9 patients remained carriers to the organism in which one of them was 
MRSA carrier (data not shown).   
Resistance to antibiotics:  
Figure 2 shows the antimicrobial susceptibilities of MRSA strains. All 
isolates were completely resistant to penicillin and ampicillin, while all 
isolates were 100 % susceptible to teicoplanin and vancomycin. However, 
the susceptibility to ciprofloxacin, erythromycin, gentamycin, and 
clindamycin was 71.5 %, 82.2 %, 85.8 %, 89.3 % respectively. 
The different antibiotic-resistance patterns encountered for the isolates are 
shown in Table 5. Eleven distinct patterns were identified, where 13 isolates 
were found to match antibiotype I, 2 isolates for antibiotype IV, 3 isolates 
for each antibiotypes (III and X) and 1 for each of the following 
antibiotypes: II, V, VI, VII, VIII, IX and XI. The distribution of MRSA 
isolates with respect to their antibiotypes is shown in Fig. 1. 
As shown in Table 6, the majority of isolates from patients and HCW 
showed antibiotype I with 8 and 5 isolates, respectively. The other isolates 
were scattered among the remaining antibiotypes.  
mecA gene: 
All the MRSA isolates that were detected for the presence of mecA gene 
showed a positive result. Clear bands of 533 bp were visualized under UV 
illumination (Data not shown).  
MLRFT:  
MLRFT differentiated the 28 isolates into 8 RFTs. The distribution of the 
isolates in the 8 RFT is shown in Table 8. Twenty-two (78.5 %) of the 28 
isolates were grouped into four RFTs. The remaining six MRSA isolates 
were scattered among additional four RFTs.    
 Correlation between antibiogram types and RFTs 
 
As shown in Table 10, three of six isolates belonging to the restriction 
fragment type AAAAAAA had the antibiogram type I, the other 3 had the 
antibiotype X. All the isolates belonging to the types AAABCBC, 
AAJBCBC, BBBBBAB had antibiotype I. However, the isolates that belong 
to the type AAACCAA had different antibiotypes. Three of the 4 isolates 
that belong to the type CAACAC had the antibiotype III; the last isolate had 
the type VI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Table 3: Nasal carriage of methicillin susceptible and methicillin resistant S. 
aureus among patients admitted to different units of Ramallah hospital. 
Samples were collected between October 2003 and October 2004. 
 
 
Patients in Ramallah hospital 
Ward No. of 
specimens 
No. of 
 S. aureus  
MRSA %  of 
S. aureus 
%  of 
MRSA 
Medical  299 93 5 31.1 33.3 
ICU 108 25 4 23.1 26.6 
CSICU 88 22 1 25 6.6 
SUR 132 23 4 17.4 26.6 
P.W 112 27 1 24.1 6.6 
OBS 104 28 0 26.9 0.00 
Total 843 218 15 25.8 6.8 
 
* % of S. aureus = (No.of S. aureus isolates (ward)/ no. of specimens 
(ward))         X 100 
* % of MRSA = (No. of MRSA isolates (ward) / total no. of MRSA isolates)  
X 100 
 
*Other three MRSA isolates were collected from patients, one of them is a 
clinical isolate (caused an infection to a patient) and the other 2 were 
isolated from the nares of 2 patients who are screened after one week of 
admission to the hospital. 
 
 
 
 
 
 
 
 
 
  
 
 
 
Table 4: Nasal carriage of methicillin susceptible and methicillin resistant S. 
aureus among health care workers at Ramallah hospital. Samples were 
collected from 72 HCW working at different units at the hospital. 
 
Healthcare Workers 
Ward No. of 
specimens 
No. of S. 
aureus 
MRSA % of S. 
aureus 
% of  
MRSA 
Medical 11 4 1 36.36 10 
ICU 15 4 4 26.6 40 
CSICU 22 6 5 27.27 50 
SUR 4 0 0 0 0 
P.W 12 1 0 8.3 0 
OBS 8 0 0 0 0 
Total 72 15 10 20.8 66.6 
 
 
* % of S. aureus = (No.of S. aureus isolates (ward)/ No. of specimens 
(ward)) X 100 
* % of MRSA =   (No. of MRSA isolates (ward)/ total No. of MRSA 
isolates) X 100 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Table 5: Antibiogram types of the 28 MRSA isolates retrieved in this study. 
 
Isolates Susceptibility to the following antibiotics 
Type No. Ox Tec Cn Cip E Amp Va Te P Kf DA 
I 13 R S S S S R S S R S S 
II 1 R S R S S R S S R S S 
III 3 R S S R S R S S R S S 
IV 2 R S S R R R S S R R R 
V 1 R S R R R R S R R R R 
VI 1 R S S R S R S S R R S 
VII 1 R S R R S R S S R R S 
VIII 1 R S S S R R S S R S S 
IX 1 R S R R R R S R R R S 
X 3 R S S S S R S S R R S 
XI 1 R S S S S R S R R   S   S  
  
 Ox: oxacillin, Tec: teicoplanain, Cn: gentamicin, Cip: ciprofloxacin, 
E: erythromycin, Amp: ampicillin, Va: Vancomycin, Te: tetracycline,  
P: penicillin, Kf: cephalothin, Da: clindamycin. 
S: Sensitive, R: Resistance 
 
 
 
 
Table 6: Distribution of the 11 antibiogram types among patients and health 
care workers 
 I II III IV V VI VII VIII IX X XI 
Patients 8 0 2 2 1 0 1 1 1 2 0 
HCW 5 1 1 0 0 1 0 0 0 1 1 
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Figure 1: Distribution of the 28 MRSA isolates among the different11 
antibiotypes. The antibiotic susceptibility of all isolates was performed by 
the disk agar diffusion method on Muller- Hinton agar. Zones of inhibition 
were determined after incubation at 35°C for 24 hrs. The following 
antibiotics were tested: ciprofloxacin 5 μg, penicillin 10 μg, gentamycin 10 
μg, tetracycline 30 μg, clindamycin 2 μg, ampicillin 10 μg, tiecoplanin 30 
μg, erythromycin 15 μg, vancomycin 30 μg, oxacillin 1 μg, cephalothin 30 
μg. 
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Figure 2: Susceptibility of the MRSA isolates to the different 
antibiotics used for preparation of antibiogram. The antibiogram 
was performed as described in the legend of Figure 1. 
 
 
 
 
Table 7: Distribution of MRSA antibiogram types among the different 
hospital units (patients and health care workers). 
 
 
 
Unit 
Antibiogram Type 
 І      ІІ     ІІІ     ІV     V    VІ   VІІ   VІІІ  ІX    X      XІ     Total  
Medical  3 0 1 0 0 0 1 1 1 1 0 8 
ICU 3 0 1 2 1 1 0 0 0 1 0 9 
CSICU 4 1 0 0 0 0 0 0 0 1 1 7 
SUR 2 0 1 0 0 0 0 0 0 0 0 3 
PW 1 0 0 0 0 0 0 0 0 0 0 1 
OBS 0 0 0 0 0 0 0 0 0 0 0 0 
Total 13 1 3 2 1 1 1 1 1 3 1 28 
 
 
 
 Table 8: MLRFT genotypes of the MRSA isolates retrieved in this study. 
Only genotypes that match the isolates retrieved in this study are shown. 
  
No. of 
isolate 
arcC aroE glpF gmk pta Tpi yqiL 
6 A A A A A A A 
8 A A A C C A A 
2 A A J B C B C 
4 C A A A C A C 
1 A A A A C A A 
4 A A A B C B C 
1 B B B B B A B 
1 B A A A C A C 
*    1  A A A C A C 
 
MLRFT was defined by the combination of alleles at the seven loci (e.g. 
RFT-AAACCAA in the order RFT-arcC-aroE-glpF-gmk-pta-tpi-yqiL). 
RFTs retrieved in this study are AAAAAAA, AAACCAA, AAJBCBC, 
CAAACAC, AAAACAA, AAABCBC, BBBBBAB and BAAACAC 
 
* isolate no. 28 has not been classified, the arcC gene in this isolate cannot 
be amplified, this may be referred to a mutation that may occurred in this 
house keeping gene.( This may be confirmed by sequencing) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 9:  Distribution of RFTs among patients and health care workers 
 
RFTs patients HCW 
AAAAAAA 5 1 
AAACCAA 5 3 
AAJBCBC 1 1 
CAAACAC 2 2 
AAAACAA 0 1 
AAABCBC 3 1 
BBBBBAB 0 1 
BAAACAC 1 0 
total 17 10 
 
 
 
Table 10: Correlation between antibiogram and MLRFT types of MRSA. 
 
 
RFT 
genotype 
No. of 
MRSA 
isolates 
 
Antibiotype 
 
I II III IV V VI VII VIII IX X XI 
AAAAAAA 6 3         3  
AAAACAA 1           1 
AAABCBC 4 4           
AAACCAA 8 3 1  2   1 1    
AAJBCBC 2 2           
BBBBBAB 1 1           
BAAACAC 1         1   
CAAACAC 4   3   1      
Total 27 13 1 3 2 0 1 1 1 1 3 1 
 
 
 
 
 
 
 
 
 
Figure 4: MLRFT genotypes. A fragment of about 450 bp from seven 
housekeeping genes in MRSA were PCR-amplified using different sets of 
primers. Folowed by digestion of 10 µl of PCR products with one or two 
restriction enzymes specific for each fragment (a-g). Restriction fragments 
were analyzed by electrophoresis on a 4 % agarose gel. The size of 
fragments was determined by comparison to a 50 bp ladder ( shown in the 
first left lane of each gel) and then the genotype was identified by 
comparison to MLFRT genotype patterns described by (5). The gene name 
and restriction enzymes are shown below along with each gel photograph. 
Only a representative gel for each genotype is shown. All PCR and 
restriction experiments were performed in duplicates.  
 
 
 
(a) arcC gene      HinfI 
      B  A A A A A C A A C A A A A  B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 (b) aroE gene        AluI & CfoI 
    A  A  A  A  A  A  A  B  A A  A  A  A 
 
 
 
 
 
 
(c) glpF gene        Tsp5091 
        J A  A A  A  A  A A A A  j  A  A  A   
 
 
 
 
 
 
 
 
 (d) gmk gene        CfoI 
     B B  C  B  A A A A C A A  B C A A 
 
 
 
 
 
 
 
(e) pta gene        RsaI 
    C  C  C  C  C  C C  B C  C  A  C  C 
 
 
 
 
 
 
 
 
  
 
(f) tpi       BbuI & MboI 
          A A A  B   A A A A A  A  A    B 
 
 
 
 
 
 
(g) yqil        VspI & DdeI 
    C  C  A  C A A  C A A  C  A C A A A 
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Discussion 
Methicillin resistant Staphylococcus aureus (MRSA) is a growing problem 
both in hospitals and in the community. Upon its introduction, MRSA 
quickly became known for its ability to cause large hospital outbreaks. Most 
strains of MRSA are sporadic (recovered only from a few patients) but a few 
strains have the ability to spread very rapidly throughout an institution and 
reach the epidemic level (1). 
In general, most hospital-acquired infections caused by MRSA (HA-MRSA) 
are associated with a relatively small number of epidemic clones spread over 
continents including Iberian (ST247-SCCmec IA), Brazilian ( ST239-III), 
New York/Japan (ST5-II), Pediatric (ST5-IV), EMRSA-16 (ST36-II), 
EMRSA-15(ST22-IV), and Berlin ( ST45-IV) clones (2, 50). Community 
acquired MRSA (CA-MRSA) has emerged as a new pathogen, it is noted 
that these isolates are not clonally related to HA-MRSA international clones. 
Moreover, CA-MRSA are susceptible to antimicrobial drugs (50). 
In order to control the spread of MRSA a clear picture of the variety and 
distribution of the local types is necessary. This can only be based on strain 
typing studies (43). 
 In this study, we investigated the prevalence of MRSA among patients 
recently admitted to Ramallah hospital. The prevalence of nasal carriage of 
S. aureus was 25.8 % among these patients. Whereas, five of the six hospital 
wards studied showed a prevalence of S. aureus carriage that ranged from 
23.1-31.1%, the sixth ward (surgical ward) showed a prevalence rate of 
17.4%. The high prevalence rate observed in this study was within the 
prevalence ranges reported in previous surveys of patients on admission 
from other countries such as USA, UK, Israel, Spain and Netherlands (26, 
49, 69, 64, 4). In this study, the prevalence of MRSA nasal carriage was 
6.8% among patients recently admitted to Ramallah Hospital. However, only 
the medical and the ICU units showed a consistently high prevalence rate of 
S. aureus and MRSA. These figures are worrying, but are still within the 
prevalence ranges reported for patients on admission from other countries (4, 
3, 64). Considering the unrestricted, inappropriate use of antibiotics and the 
lack of antibiotic policies in Palestine, the increasing spread of MRSA is 
expected.  
The health care workers at Ramallah hospital showed a high incidence of 
colonization with strains of MRSA (66.6 %). This high carriage rate of 
HCW indicates that the hospital lacks a screening and control program for 
the employees. This is extremely dangerous for other patients served by 
these carriers. In fact, they are probably the most significant source for 
transmitting MRSA to their patients as well as to other health care workers. 
The highest prevalence rate of S. aureus and MRSA carriage among HCWs 
was in the CSICU (50 %), ICU (40 %) and medical unit (10 %). However, 
the CSICU and ICU showed a consistently high prevalence rate of S. aureus 
and MRSA but no such correlation could be observed regarding the medical 
ward. Moreover, from the six hospital wards, only the ICU unit showed a 
consistently high prevalence rate of both S. aureus and MRSA and in both 
HCWs and patients (Tables 3 & 4).  
Our bacterial collection of MRSA strains showed a broad range of antibiotic 
resistance patterns (Table 5). The antibiogram typing revealed that 
antibiogram type I (resistant to oxacillin, penicillin and ampicillin) was 
predominant among 46.4 % of all the nasal isolates (in patients and health 
care workers). This result indicates that the hospital environment may 
represent a reservoir for this type. Additionally, each of antibiotype III and 
X was found in 10.7 % of the isolates and the remaining isolates were 
scattered among the rest eight antibiotypes. Moreover, the antibiotypes tend 
to be scattered among the different hospital wards and no clustering of any 
antiobiotype could be observed in any hospital ward.   
Some strains were multiresistant, i.e., they were resistant to beta-lactam 
antibiotics as well as to Cip, Da, Ery, Cn and variably resistant to other 
antibiotics (Table 5). Unexpectedly, most of our MRSA isolates were 
variably susceptible to several, or virtually all non Beta-lactam antibiotics, 
this may be due to the lack of genes encoding resistance to these drugs that 
are usually conserved within mecA DNA. Multisusceptible MRSA strains 
have gradually been reported in the European region, Singapore, Greek and 
Australia (48, 47, 23, 41). Gentamycin-sensitive methicillin resistant S. 
aureus (GS-MRSA), as either a nosocomial or community – acquired 
infection phenomenon, is worldwide now. GS-MRSA with increased 
susceptibility to other antimicrobials has recently been reported in six widely 
dispersed hospitals in France and one in the West Indies. Nimmo et al (41) 
reported that Community acquired GS-MRSA strains were not related to 
nosocomial GR-MRSA. However phage typing results suggest that they are 
related to GS-MRSA as previously reported in New Zealand (41).    
Molecular typing, complemented by conventional methods provides a 
sensitive and specific approach for outbreak tracking, and its usefulness in 
nosocomial epidemiology is very well documented (26, 55). MLRFT is a 
useful tool for the characterization of S. aureus strains (5). Besides the low 
cost, rapidity and simplicity of this technique it possesses two important 
virtues of MLST, the strain characterization approach that is highly 
discriminating and it is portable. Moreover, because both MLRFT and 
MLST rely on the same sequence database, it is possible to work back and 
forth between the typing systems. Indeed MLRFT captures about 95 % of 
the discriminating power of MLST that makes it appear counterintuitive, 
given that MLRFT detects far fewer alleles per locus than MLST (5).These 
virtues make the technique widely applicable, particularly in clinical 
research settings for strain screening purposes and in the developing world, 
where the sequencing technology required for MLST is not readily available.   
In our study, the 28 MRSA isolates were distributed among eight RFTs 
(Table 8). Because of the translational property between MLRFT and 
MLST, four of the common MRSA RFTs observed in this study could be 
provisionally identified as belonging to STs of known clonal lineages. 
Where the RFTs genotypes – CAAACAC, AAACCAA , BBBBBAB and 
BAAACAC correspond to the archaic/Iberian/clone V group, the 
NewYork/Pediatric/Japan group, the epidemic MRSA type 16 (EMRSA – 
16) group, and the Brazilian clone, respectively (5, 68). 
The other four MRSA RFTs (AAAAAAA, AAJBCBC, AAAACAA, 
AAABCBC) retrieved in this study, did not correspond to any of the major 
lineages that have been determined previously, so that they may be regarded 
as sporadic strains. 
The Iberian clone was first reported in Spain in 1989 and since then has been 
reported in Portugal, Italy, the UK, Germany, Belgium, Switzerland, France, 
Czech Republic, Poland, and the USA (6, 33). The Brazilian clone was first 
described in 1992 in Brazil and then Portugal, Argentina, Uruguay, Chile 
and Chez Republic (58). The New York/Japan clone was identified as the 
dominant MRSA in Hospitals in metropolitan, New Jersey, Pennsylvania, 
and Connecticut, and also in one hospital in Tokyo, Japan. The pediatric 
clone was first reported in a pediatric hospital in Portugal in 1992 and later 
reported in Poland, USA, Argentina, and Colombia . E-MRSA 16 is most 
frequently isolated from UK hospitals (43).  
According to Oliveria et al (43); most isolates of the Iberian clone, 
NewYork /Japan, and Hungarian clones are resistant to most commonly used 
antimicrobial agents, with the exception of the co-trimoxazole. While the 
Brazilian clone was only susceptible to septomycin and the pediatric clone 
was only resistant to Oxacillin, Penicillin, Gentamycin, and occasionally 
Erythromycin. But all clones were susceptible to Vancomycin (43).  
Although reports indicated that Iberian and New York/Japan Clones usually 
show multidrug resistance, our strains that confirmed to be from these clones 
by MLRFT typing were susceptible to most of the antibiotics.  
Some RFTS exhibited a clear association with specific antimicrobial 
susceptibility patterns; others did not as shown in Table10. The 13 MRSA 
isolates of antbiotype I were scattered among five RFT genotypes (Table 10) 
and did not show preference for a specific RFT genotype. In contrast the 3 
isolates in each antibiotype III and X were clustered into RFT genotypes 
CAAACAC and AAAAAAA, respectively. For the remaining MRSA 
isolates, each one or two isolates were associated with a different antibiotype 
and thus no specific clustering with RFT genotypes could be observed. 
Despite the low number of MRSA isolates grouped into antibiotypes III and 
X (3 isolates each), their correlation with specific RFT genotypes is 
interesting and should be further investigated on a large sample of MRSA 
isolates. However, the lack of a correlation between the antibiotypes and the 
RFT genotypes could be explained by the fact that the seven genes used to 
establish the RFT genotypes are housekeeping genes and are probably not 
involved directly with virulence of the isolate. But a possible correlation 
between the antibiotypes and the RFT genotypes cannot be ruled out based 
on our study, partly because of low sample number. Furthermore, such a 
correlation can be established only by investigating a larger sample of 
MRSA isolates and probably by analyzing some genes directly involved in 
the virulence of S. aureus and MRSA in particular such as the mecA gene 
and PVL gene (70, 50)..      
In conclusion, the prevalence of average nasal carriage of S. aureus among 
patients admitted to Ramallah hospital was 25.8 %, whereas the prevalence 
of MRSA was 6.8 %. By using MLRFT genotyping method 14 MRSA 
isolates belong to the epidemic clones: Iberian, Brazilian, NewYork/Japan, 
EMRSA-16. The other 13 isolate do not correspond to any of the major 
lineages that spread internationally. Most of our MRSA clones are 
susceptible to non beta-lactam antibiotics. 
 
 
 
 
 
 
 
 
 
 Recomendations 
• Antibiotic resistant MRSA are increasingly isolated and are a serious 
problem in Palestine indicating the need for continuous surveillance 
programs to generate accurate local antimicrobial susceptibility data 
and studying alternative antibiotic therapies.  
• Wise use of antibiotics based on monitoring programs in the health 
care systems will drastically decrease the incidence of multidrug 
resistant MRSA isolates. 
• Annual routine screening for MRSA should be implemented in order 
to evaluate the size of the problem in palestine.  
• Combination of results for more than one genotyping is more 
powerful in differentiating between epidemiologically related and 
unrelated MRSA strains. 
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